Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Operating Leases (2021 - 2025)

Prime Medicine's Operating Leases history spans 5 years, with the latest figure at $108.3 million for Q4 2025.

  • For Q4 2025, Operating Leases rose 191.26% year-over-year to $108.3 million; the TTM value through Dec 2025 reached $108.3 million, up 191.26%, while the annual FY2025 figure was $108.3 million, 191.26% up from the prior year.
  • Operating Leases reached $108.3 million in Q4 2025 per PRME's latest filing, down from $118.1 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $118.1 million in Q3 2025 to a low of $3.1 million in Q4 2021.
  • Average Operating Leases over 5 years is $37.8 million, with a median of $19.9 million recorded in 2022.
  • Peak YoY movement for Operating Leases: soared 753.34% in 2024, then tumbled 83.63% in 2025.
  • A 5-year view of Operating Leases shows it stood at $3.1 million in 2021, then skyrocketed by 455.41% to $17.1 million in 2022, then crashed by 74.45% to $4.4 million in 2023, then skyrocketed by 753.34% to $37.2 million in 2024, then skyrocketed by 191.26% to $108.3 million in 2025.
  • Per Business Quant, the three most recent readings for PRME's Operating Leases are $108.3 million (Q4 2025), $118.1 million (Q3 2025), and $112.5 million (Q2 2025).